» Articles » PMID: 34334100

Hematological and Biochemical Parameters As Diagnostic and Prognostic Markers in SARS-COV-2 Infected Patients of Pakistan: a Retrospective Comparative Analysis

Overview
Journal Hematology
Specialty Hematology
Date 2021 Aug 2
PMID 34334100
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

This study was conducted to investigate alteration in blood parameters and their association with the presence, severity, and mortality of COVID-19 patients as the data on hematological abnormalities associated with the Pakistani COVID-19 patients is limited. A double-centered, hospital-based comparative retrospective case study was conducted, to include all the admitted patients ( = 317) having COVID-19 Polymerase chain reaction (PCR) positive. The control group ( = 157) tested negative for COVID-19. Of 317 admitted cases, the majority were males = 198 (62.5%). Associated comorbidities, lower lymphocytes, platelets, and higher White blood cells, neutrophil, neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were found in COVID-19 cases as compared to healthy controls ( < 0.001 for all). The biochemical parameters of cases including Ferritin, D-Dimer, CRP, IL-6, LDH, ALT, AST, and APTT also showed a statistically significant difference compared with standard values ( < 0.001 for all). However, their comparison with a severity level of the severe and non-severe groups showed significance for WBCs, neutrophils, NLR ( < 0.001 for all), and PLR ( = 0.06) only. Receiver operating characteristic curve analysis showed that NLR had the highest area under curve (0.84) followed by 1/lymphocyte (0.82), neutrophils (0.74), PLR (0.67),1/platelets (0.68) and WBC's (0.65). Comparison of cases and controls with recommended cut-off values derived from sensitivity and 1-specificity was also done ( < 0.001). Monitoring all the hematological and biochemical parameters including novel hemograms NLR, PLR can aid clinicians to identify potentially severe cases at early stages and initiate effective management in time which may reduce the overall mortality of COVID-19 patients.

Citing Articles

An approach to COVID‑19 and oncology: From impact, staging and management to vaccine outcomes in cancer patients: A systematic review and meta‑analysis.

Ahmed R, Aldalbahi A, Alhumaidan N, Alotaibi T, Alharbi M, Alharbi M Exp Ther Med. 2025; 29(2):37.

PMID: 39776889 PMC: 11705223. DOI: 10.3892/etm.2024.12787.


Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies (Review).

Zhang T, Yang D, Tang L, Hu Y Mol Med Rep. 2024; 30(2).

PMID: 38940338 PMC: 11228696. DOI: 10.3892/mmr.2024.13272.


What Is the Impact of Baseline Inflammatory and Hemostatic Indicators with the Risk of Mortality in Severe Inpatients with COVID-19: A Retrospective Study.

Zhu H, Li Y, Su H, Yan C, Xin W, Ying K Clin Appl Thromb Hemost. 2024; 30:10760296241255959.

PMID: 38831596 PMC: 11151767. DOI: 10.1177/10760296241255959.


Assessment of the Clinical Value of Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma.

Chen X, Mohammed A, Li C Clin Appl Thromb Hemost. 2024; 30:10760296231221535.

PMID: 38591958 PMC: 11005495. DOI: 10.1177/10760296231221535.


Association of haemato-biochemical indices and blood composite ratios with microfilaridermia in Onchocerciasis patients.

Debrah L, Gyasi C, Ahiadorme M, Rahamani A, Opoku V, Obeng P BMC Infect Dis. 2024; 24(1):384.

PMID: 38589790 PMC: 11003075. DOI: 10.1186/s12879-024-09278-0.